Previous 10 | Next 10 |
Eight small companies and four SPACs entered the public market this past week. Continuing a 4Q trend, all eight deals priced below the midpoint; the average IPO priced 11% below the midpoint, traded up 1% on its first day, and finished the week up 3%. Four of the eight had significant insider ...
NC318 was well tolerated Single agent activity observed in multiple tumor types, including a CR and a PR in NSCLC Initiated Phase 2 portion of the Phase 1/2 monotherapy trial and plans for a combo trial with standard of care chemotherapies BELTSVILLE, Md., Nov. 09, 2019 (GLOBE NEWSWIR...
Gainers: Constellation Pharmaceuticals (NASDAQ: CNST ) +99% . More news on: Constellation Pharmaceuticals, Inc., FuelCell Energy, Inc., comScore, Inc., Stocks on the move, Read more ...
Fluidigm (NASDAQ: FLDM ) -31% on Q3 results . More news on: Fluidigm Corporation, Plantronics, Inc., Amneal Pharmaceuticals, Inc., Stocks on the move, Read more ...
Shares of NextCure (NASDAQ: NXTC) , a clinical-stage biopharmaceutical company developing new cancer drugs, exploded higher this morning. Updated clinical trial results from a handful of non-small cell lung cancer patients sent the biotech stock 225.8% higher as of 3:22 p.m. EST on Tuesday....
Gainers : NextCure (NASDAQ: NXTC ) +183% . Fulgent Genetics (NASDAQ: FLGT ) +35% . NIO (NYSE: NIO ) +28% . Acorda Therapeutics (NASDAQ: ACOR ) +26% . EverQuote (NASDAQ: EVER ) +27% . Forterra (NASDAQ: FRTA ) +25% . Gaia (NASDAQ: GAIA ) +23% . Agile Therapeutics (NASDAQ: AGRX ) +23%...
Thinly traded NextCure ( NXTC +60.7% ) is up on almost an 8x surge in volume, albeit on turnover of only 722K shares, on the expiration of the lockup period today. More news on: NextCure, Inc., Healthcare stocks news, Stocks on the move, Read more ...
BELTSVILLE, Md., Nov. 04, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. , a clinical-stage biopharmaceutical company committed to discovering and developing next-generation immunomedicines for cancer and other immune-related diseases, today announced that the company will host and webcast an eve...
For an equity market that has hit all-time highs on multiple occasions during this year, one would think that investors would be salivating over IPOs for a chance to "get in from the beginning" and bidding them higher in the process. The reality, though, is that IPOs have been one of the more ...
Seven biotech companies with initial valuations north of $1 billion began trading during the first nine months of 2019. Overall, these companies performed well. Their average and median returns were 13% and 14% respectively. In comparison, the SPDR S&P 500 ETF (NYSEARCA: SPY) and the Fide...
News, Short Squeeze, Breakout and More Instantly...
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings...
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43% Data to be presented June 1, 2024,...
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE...